Mohammed Umar, Omar Hyder, Muttiullah Mutti, Abdul Naeem, Hamamatul, Mohammed Imran, Atif Nazeer.
Peg Interferon, Ribavirin, Thymosin Alpha 1 and Amantadine (quadruple therapy) in Chronic Hepatitis C3a patients who are non-responders to Interferon-Alpha plus Ribavirin.
Pak J Gastroenterol Jan ;20(1):18-24.

We evaluated the efficacy of a quadruple therapy regimen using pegylated interferon, ribavirin, amantadine and thymosin alpha in patients of chronic hepatitis C who had not responded to previous therapy with the standard regimen of interferon alpha and ribavirin for 24 weeks. In this open label study, 18 patients of chronic hepatitis C who had not responded to previous therapy with the standard regimen of interferon alpha and ribavirin were retreated with a quadruple regimen using pegylated interferon, ribavirin, amantadine and thymosin alpha-1 for 24 weeks and followed up for another 24 weeks. The primary end point of the study was undetectable HCV-RNA by PCR at 24 weeks (sustained viral clearance) after completion of treatment. At the end of the study, 7 out of 18 patients (39%) had a sustained viral response to the quadruple drug therapy. All 18 patients (100%) showed decrease in the load of HCV RNA in their serum. The data for response to quadruple therapy with pegylated interferon, ribavirin, amantadine and thymosin alpha-1 suggests that the regimen may be a useful addition to the current practices in treatment of non-responders to the standard therapy.

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com